These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 36239794)

  • 1. Identification of tumor-specific neoantigens and immune clusters of hepatocellular carcinoma for mRNA vaccine development.
    Li YF; Hou QQ; Zhao S; Chen X; Tang M; Li L
    J Cancer Res Clin Oncol; 2023 Feb; 149(2):623-637. PubMed ID: 36239794
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of tumor antigens and immune subtypes of pancreatic adenocarcinoma for mRNA vaccine development.
    Huang X; Zhang G; Tang T; Liang T
    Mol Cancer; 2021 Mar; 20(1):44. PubMed ID: 33648511
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification and validation of palmitoylation metabolism-related signature for liver hepatocellular carcinoma.
    Feng R; Cheng D; Chen X; Yang L; Wu H
    Biochem Biophys Res Commun; 2024 Jan; 692():149325. PubMed ID: 38056161
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic and immunological potential of PPM1G in hepatocellular carcinoma.
    Lin YR; Yang WJ; Yang GW
    Aging (Albany NY); 2021 May; 13(9):12929-12954. PubMed ID: 33952716
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PDCL3 is a prognostic biomarker associated with immune infiltration in hepatocellular carcinoma.
    Jin W; Wang G; Dong M; Wang X
    Eur J Med Res; 2024 Mar; 29(1):177. PubMed ID: 38494503
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Construction of liver hepatocellular carcinoma-specific lncRNA-miRNA-mRNA network based on bioinformatics analysis.
    Wang R; Hu X; Liu X; Bai L; Gu J; Li Q
    PLoS One; 2021; 16(4):e0249881. PubMed ID: 33861762
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identifying Potential Tumor Antigens and Antigens-Related Subtypes in Hepatocellular Carcinoma for mRNA Vaccine Development.
    Liao W; Shi Z; Tang H; Wu T; Zhang C; He Y; Zou R; Wang L
    J Oncol; 2022; 2022():6851026. PubMed ID: 36072981
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comprehensive analysis of N
    Zhu HX; Lu WJ; Zhu WP; Yu S
    J Clin Lab Anal; 2021 Dec; 35(12):e24071. PubMed ID: 34741346
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comprehensive analysis of diverse programmed cell death patterns in the prognosis, tumor microenvironment and drug sensitivity in hepatocellular carcinoma.
    Yu Y; Lou Y; Zhu J; Wang X
    Medicine (Baltimore); 2023 Dec; 102(48):e36239. PubMed ID: 38050240
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preparation of hepatocellular carcinoma mRNA vaccines based on potential tumor targets and immunophenotypes.
    Wang HK; Xu XH; Wang SM; Zhang HY
    Transl Cancer Res; 2024 Jan; 13(1):173-190. PubMed ID: 38410201
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlation analysis of RDM1 gene with immune infiltration and clinical prognosis of hepatocellular carcinoma.
    Qiu C; Li Z; Cao W; Cai X; Ye L; Zhang C; Ma Y; Wang X; Yang Y
    Biosci Rep; 2021 Sep; 41(9):. PubMed ID: 34435618
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Pyroptosis-Related Gene Signature to Predict Patients' Prognosis and Immune Landscape in Liver Hepatocellular Carcinoma.
    Wang J; Huang Z; Lu H; Zhang R; Feng Q; He A
    Comput Math Methods Med; 2022; 2022():1258480. PubMed ID: 35242200
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High expression of RNF31 is associated with tumor immune cell infiltration and leads to poor prognosis in liver hepatocellular carcinoma.
    Xi G; Cheng R; Liang L; Che N; Wang Y; Zhao N; Liang X; Shao B; Zhao X; Zhang D
    Sci Rep; 2023 Apr; 13(1):6957. PubMed ID: 37117215
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Integrative Multi-Omics Analysis of Identified Ferroptosis-Marker RPL8 as a Candidate Oncogene Correlates with Poor Prognosis and Immune Infiltration in Liver Cancer.
    Fan S; Zhang S; Kong D; Wang H; Shi Y; Wang Z; Zheng H
    Comb Chem High Throughput Screen; 2023; 26(7):1298-1310. PubMed ID: 36017842
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A pan-cancer analysis of the oncogenic role of ribonucleotide reductase subunit M2 in human tumors.
    Li Y; Fu W; Geng Z; Song Y; Yang X; He T; Wu J; Wang B
    PeerJ; 2022; 10():e14432. PubMed ID: 36518297
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of Neoantigens and Construction of Immune Subtypes in Prostate Adenocarcinoma.
    Gao Y; Wang G; Chen Y; Zhang M; Gao W; Shang Z; Niu Y
    Front Genet; 2022; 13():886983. PubMed ID: 35547260
    [No Abstract]   [Full Text] [Related]  

  • 17. Identification of tumor antigens and immune landscapes for bladder urothelial carcinoma mRNA vaccine.
    Sun Z; Jing C; Zhan H; Guo X; Suo N; Kong F; Tao W; Xiao C; Hu D; Wang H; Jiang S
    Front Immunol; 2023; 14():1097472. PubMed ID: 36761744
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune infiltration-associated serum amyloid A1 predicts favorable prognosis for hepatocellular carcinoma.
    Zhang W; Kong HF; Gao XD; Dong Z; Lu Y; Huang JG; Li H; Yang YP
    World J Gastroenterol; 2020 Sep; 26(35):5287-5301. PubMed ID: 32994688
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cuproptosis-Related Signature Predicts the Prognosis, Tumor Microenvironment, and Drug Sensitivity of Hepatocellular Carcinoma.
    Qi X; Guo J; Chen G; Fang C; Hu L; Li J; Zhang C
    J Immunol Res; 2022; 2022():3393027. PubMed ID: 36438201
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery and characterization of tumor antigens in hepatocellular carcinoma for mRNA vaccine development.
    Fu J; Chen F; Lin Y; Gao J; Chen A; Yang J
    J Cancer Res Clin Oncol; 2023 Jul; 149(7):4047-4061. PubMed ID: 36038676
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.